Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICALS
NCT00541047Phase 3Completed
- Sponsor
- University College London
- Start
- Nov 2007
- Primary completion
- Jul 2022
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of goserelin, leuprolide and bicalutamide in prostate cancer (PCa) (5 arms), sponsored by University College London. Primary endpoints: Disease-specific survival at 12 years and Freedom from distant metastases at 12 years. Started Nov 2007; status: completed.
02
Drugs
goserelinleuprolidebicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00541047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541047.